Rua Bioscience (NZSE:RUA) EV-to-EBIT : -0.47 (As of Jun. 19, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Rua Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rua Bioscience's Enterprise Value is NZ$5.57 Mil. Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NZ$-11.78 Mil. Therefore, Rua Bioscience's EV-to-EBIT for today is -0.47.

The historical rank and industry rank for Rua Bioscience's EV-to-EBIT or its related term are showing as below:

NZSE:RUA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.66 Med: -0.9 Max: -0.24
Current: -0.48

During the past 3 years, the highest EV-to-EBIT of Rua Bioscience was -0.24. The lowest was -1.66. And the median was -0.90.

NZSE:RUA's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs NZSE:RUA: -0.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Rua Bioscience's Enterprise Value for the quarter that ended in Dec. 2023 was NZ$16.64 Mil. Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NZ$-11.78 Mil. Rua Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -70.80%.

Rua Bioscience EV-to-EBIT Historical Data

The historical data trend for Rua Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rua Bioscience EV-to-EBIT Chart

Rua Bioscience Annual Data

Trend

Jun21

Jun22

Jun23

EV-to-EBIT

-6.23

-5.39

-1.53

Rua Bioscience Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-5.39	-	-1.53	-

Competitive Comparison of Rua Bioscience's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rua Bioscience's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rua Bioscience's EV-to-EBIT falls into.

Rua Bioscience EV-to-EBIT Calculation

Rua Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5.574	/	-11.784
	=	-0.47

Rua Bioscience's current Enterprise Value is NZ$5.57 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NZ$-11.78 Mil.

Rua Bioscience (NZSE:RUA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Rua Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-11.784	/	16.64432
	=	-70.80 %

Rua Bioscience's Enterprise Value for the quarter that ended in Dec. 2023 was NZ$16.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NZ$-11.78 Mil.

Rua Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Rua Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Rua Bioscience (NZSE:RUA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rua Bioscience Ltd (NZSE:RUA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Commerce Place, Awapuni, Gisborne, NZL, 4071

Website

https://www.ruabio.com

Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Germany and New Zealand.

Rua Bioscience (NZSE:RUA) Headlines

No Headlines